Biophytis SA
PAR:ALBPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pathward Financial Inc
SWB:FM7
|
US |
Biophytis SA
Free Cash Flow
Biophytis SA
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biophytis SA
PAR:ALBPS
|
Free Cash Flow
-€16.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Free Cash Flow
-€57.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Free Cash Flow
-€29.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-7%
|
|
|
Inventiva SA
PAR:IVA
|
Free Cash Flow
-€162m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Free Cash Flow
-$121m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-14%
|
|
|
Abivax SA
PAR:ABVX
|
Free Cash Flow
-€154.7m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-26%
|
|
Biophytis SA
Glance View
Biophytis SA is a holding company. The company is headquartered in Paris, Ile-De-France and currently employs 24 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
See Also
What is Biophytis SA's Free Cash Flow?
Free Cash Flow
-16.7m
EUR
Based on the financial report for Jun 30, 2025, Biophytis SA's Free Cash Flow amounts to -16.7m EUR.
What is Biophytis SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-28%
Over the last year, the Free Cash Flow growth was -53%. The average annual Free Cash Flow growth rates for Biophytis SA have been 7% over the past three years , -28% over the past five years .
